Mairs & Power, an investment advisor, released the “Mairs & Power Balanced Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The stock market reached a record high in February. However, tariff uncertainty in March led to a fall in equities, while fixed income benefited from perceived safety. The fund ended the quarter up 0.04%. The fund outperformed the benchmark composite indexes (60% S&P 500 Total Return Index and 40% Bloomberg U.S. Government/Credit Bond Index), down 1.48%, and the Morningstar Moderate Allocation peer group, which fell 0.34%. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its first-quarter 2025 investor letter, Mairs & Power Balanced Fund highlighted stocks such as Bio-Techne Corporation (NASDAQ:TECH). Bio-Techne Corporation (NASDAQ:TECH), with a market capitalization of $7.544 billion, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets. The one-month return of Bio-Techne Corporation (NASDAQ:TECH) was -11.74%, and its shares lost 38.07% of their value over the last 52 weeks. On May 6, 2025, Bio-Techne Corporation (NASDAQ:TECH) stock closed at $47.72 per share.

Mairs & Power Balanced Fund stated the following regarding Bio-Techne Corporation (NASDAQ:TECH) in its Q1 2025 investor letter:

"Bio-Techne Corporation (NASDAQ:TECH) underperformed due to negativity around the funding environment for biopharmaceuticals and biotech research given recent federal funding cuts and a weak venture capital funding environment. We have taken advantage of the recent weakness to add to our Bio-Techne position."Is MKS Instruments Inc. (MKSI) the Best Scientific Instruments Stock to Buy Right Now?

A scientist working on a complex photonics instruments in a sterile laboratory setting.

Bio-Techne Corporation (NASDAQ:TECH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 24 hedge fund portfolios held Bio-Techne Corporation (NASDAQ:TECH) at the end of the fourth quarter compared to 25 in the third quarter. In the second quarter of fiscal 2025, the company generated $297 million in revenues, up 9% year-over-year on both reported and organic basis. While we acknowledge the potential of Bio-Techne Corporation (NASDAQ:TECH) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

Story Continues

In another article, we covered Bio-Techne Corporation (NASDAQ:TECH) and shared Conestoga Capital Advisors' views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.

Disclosure: None. This article is originally published at Insider Monkey.

View Comments